|
| 37788412 | Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial. | J Clin Oncol | 2024 |
| 37797733 | Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study. | J Thorac Oncol | 2024 |
| 38070301 | Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review. | Lung Cancer | 2024 |
| 37788412 | Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial. | J Clin Oncol | 2024 |
| 38070301 | Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review. | Lung Cancer | 2024 |
| 37797733 | Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study. | J Thorac Oncol | 2024 |
| 35881197 | Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer. | Cancer Immunol Immunother | 2023 |
| 36369159 | Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. | J Thorac Cardiovasc Surg | 2023 |
| 35881197 | Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer. | Cancer Immunol Immunother | 2023 |
| 36327426 | Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. | J Clin Oncol | 2023 |
| 37597750 | Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. | J Thorac Oncol | 2023 |
| 37731641 | Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review. | Front Oncol | 2023 |
| 37730274 | CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity. | J Immunother Cancer | 2023 |
| 37992595 | Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). | Lung Cancer | 2023 |
| 36520037 | Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms? | Clin Cancer Res | 2023 |
| 36842467 | MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. | J Thorac Oncol | 2023 |
| 37399400 | Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring. | Proc Natl Acad Sci U S A | 2023 |
| 37146752 | Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial. | J Thorac Oncol | 2023 |
| 37023987 | Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 37076395 | RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome. | Clin Lung Cancer | 2023 |
| 36890020 | Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study. | Clin Lung Cancer | 2023 |
| 36822130 | Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study. | Eur J Cancer | 2023 |
| 37460344 | Corrigendum to "Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189" [Lung Cancer 155 (2021) 53-60]. | Lung Cancer | 2023 |
| 37327461 | First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. | J Clin Oncol | 2023 |
| 36809080 | Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. | J Clin Oncol | 2023 |
| 37429923 | Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. | Nat Med | 2023 |
| 36923158 | Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib. | JTO Clin Res Rep | 2023 |
| 37532930 | Consent document translation expense hinders inclusive clinical trial enrolment. | Nature | 2023 |
| 37597750 | Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. | J Thorac Oncol | 2023 |
| 37992595 | Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). | Lung Cancer | 2023 |
| 37731641 | Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review. | Front Oncol | 2023 |
| 37730274 | CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity. | J Immunother Cancer | 2023 |
| 37532930 | Consent document translation expense hinders inclusive clinical trial enrolment. | Nature | 2023 |
| 37460344 | Corrigendum to "Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189" [Lung Cancer 155 (2021) 53-60]. | Lung Cancer | 2023 |
| 37023987 | Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 37146752 | Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial. | J Thorac Oncol | 2023 |
| 37076395 | RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome. | Clin Lung Cancer | 2023 |
| 37399400 | Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring. | Proc Natl Acad Sci U S A | 2023 |
| 37429923 | Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. | Nat Med | 2023 |
| 37327461 | First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01. | J Clin Oncol | 2023 |
| 36890020 | Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study. | Clin Lung Cancer | 2023 |
| 36923158 | Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib. | JTO Clin Res Rep | 2023 |
| 36520037 | Is There a Place for Temozolomide plus Nivolumab among Neuroendocrine Neoplasms? | Clin Cancer Res | 2023 |
| 36809080 | Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. | J Clin Oncol | 2023 |
| 36842467 | MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. | J Thorac Oncol | 2023 |
| 36822130 | Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study. | Eur J Cancer | 2023 |
| 36369159 | Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. | J Thorac Cardiovasc Surg | 2023 |
| 36327426 | Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. | J Clin Oncol | 2023 |
| 35324247 | Facets of stigma, self-compassion, and health-related adjustment to lung cancer: A longitudinal study. | Health Psychol | 2022 |
| 35841410 | RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship. | Cancer Chemother Pharmacol | 2022 |